Komori
KYORIN Pharmaceutical (4569) · Initiative¥188 million in shares scheduled for delivery

Introduction of a Performance-Linked Share Compensation Plan

First written in FY2017-Q2. 3 of 8 entries say "Restated". Latest entry: FY2025.

8entries
10years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2017 – FY20252016: 12017: 220172018: 120182019: 120192020: 020202021: 020212022: 020222023: 120232024: 120242025: 12025
Same theme, other companies
Performance-Linked Stock Compensation through BIP and ESOP TrustsA theme 150 companies write about · 0 as a headwind · 160 as a tailwind

21 other companies' latest entry also says "Other".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 150 companies compared. The sentences above are computed from all 150.
Full recordFilings, disclosures and news, newest first
  1. FY2025¥188 million in shares scheduled for deliveryAnnual report

    「Total value of shares scheduled for delivery to officers: ¥188 million」

    The performance-linked share compensation plan continues, but the total value of shares scheduled for delivery to officers fell from the previous disclosure of ¥189 million to ¥188 million.
  2. FY2024Total value of shares scheduled for delivery: ¥189 millionAnnual report

    「Total value of shares scheduled for delivery to officers: ¥189 million」

    The performance-linked share compensation plan continues, but the total value of shares scheduled for delivery to officers fell from the previous disclosure of ¥208 million to ¥189 million.
  3. FY2023Total value of shares scheduled for delivery: ¥208 millionAnnual report

    「Total value of shares scheduled for delivery to Group officers: ¥208 million」

    The performance-linked share compensation plan continues, but the total value of shares scheduled for delivery fell from the previously disclosed ¥226 million to ¥208 million.
  4. FY2019RestatedAnnual report

    「Total value of shares scheduled for delivery to Group officers: ¥226 million」

    The performance-linked share compensation plan continues, and the company has disclosed a total value of shares scheduled for delivery of ¥226 million.
  5. FY2018RestatedAnnual report

    「Total value of shares scheduled for delivery to Group officers: ¥226 million」

    The performance-linked share compensation plan continues, and the company has disclosed a total value of shares scheduled for delivery of ¥226 million.
  6. FY2017RestatedAnnual report

    「Total value of shares scheduled for delivery to Group officers: ¥226 million」

    The performance-linked share compensation plan continues, and the company has disclosed a total value of shares scheduled for delivery of ¥226 million.
  7. FY2017-Q3AdvancedAnnual report

    「At the end of the third quarter of the current consolidated accounting period, the treasury shares held by the trust were presented as treasury shares under net assets. Their carrying amount was ¥226 million and the total number of shares was 100 thousand.」

    Following approval of the introduction of the performance-linked share compensation plan, the specific implementation status was disclosed, including the share delivery trust's holding of treasury shares.
  8. FY2017-Q2First statedAnnual report

    「At the 58th Annual General Meeting of Shareholders held on 24 June 2016, we approved the introduction of a performance-linked share compensation plan for the directors of the Company and KYORIN Pharmaceutical Co.,Ltd., a consolidated subsidiary of the Company, excluding outside directors. These individuals are referred to below as “Group officers.”」

    The introduction of a performance-linked share compensation plan using a share delivery trust for Group officers was approved.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for KYORIN Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.